• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Opinions
    • Top 30
    • Research
    • Supply Chain
    • Device Sectors
    • Directory
    • Events
    • Resources
    • Microsites
    • More
  • Magazine
  • News
  • Opinions
  • Top 30
  • Research
  • Supply Chain
  • Device Sectors
  • Directory
  • Events
  • Resources
  • Microsites
  • Current / Back Issues
    Features
    Editorial
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Reprints
    Subscribe Now
    Advertise Now
    Top Features
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    OEM News
    Supplier News
    Service / Press Releases
    Online Exclusives
    Press Releases
    People in the News
    Product & Service Releases
    Supplier News
    Medtech Makers
    Technical Features
    International News
    Videos
    Product & Service Releases
    Live From Shows
    Top News
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread

    Endoscopic Hemostasis Devices Market Valued at $730 Million

    Henry Schein Buys Majority Interest in Prism Medical Products

    Boston Scientific's Vercise Genus DBS Earns FDA Approval

    Biotech Team Develops ELISA Protocol for COVID-19 Antibody Detection
    From the Editor
    Blogs
    Guest Opinions
    Top Opinions
    Pharmaceutical Focus: A Look at Combination Products

    The Printed World: Additive Manufacturing in Medtech

    The Lost Year: 2020 Year in Review

    Extrusion Evolution

    Little Big Parts: Micromolding Under the Microscope
    Top 30 Medical Device Companies
    Market Data
    White Papers
    Top Research
    Fixing Face Mask Form and Function

    The Heart of the Matter: Trends in Cardiology

    Virtually the Same? The Challenges of Online Conferences

    Digital Health Delivers During a Year for the Ages

    Advanced Technology for Staking and Swaging Medical Plastics
    3D/Additive Manufacturing
    Contract Manufacturing
    Electronics
    Machining & Laser Processing
    Materials
    Molding
    Packaging & Sterilization
    R&D & Design
    Software & IT
    Testing
    Tubing & Extrusion
    Cardiovascular
    Diagnostics
    Digital Health
    Neurological
    Patient Monitoring
    Surgical
    Orthopedics
    All Companies
    Categories
    Company Capabilities
    Add New Company
    Outsourcing Directory
    FUTEK Advanced Sensor Technology Inc.

    Creganna Medical, part of TE Connectivity

    Medicoil

    Element

    maxon
    MPO Summit
    Industry Events
    Webinars
    Live From Show Event
    Industry Associations
    Videos
    Career Central
    eBook
    Slideshows
    Top Resources
    Meeting Critical Ventilator Product Requirements Amid Pandemic

    Impact of COVID-19 on the Medtech Supply Chain

    Finding the Upside to a Challenging Year

    Preparing Your Design Controls for FDA Approval

    A 'Trial and Error' Approach to Micromolded Parts
    Companies
    News Releases
    Product Releases
    Press Releases
    Product Spec Sheets
    Service Releases
    Case Studies
    White Papers
    Brochures
    Videos
    Outsourcing Directory
    Spectrum Plastics Group

    Concise Engineering

    Creganna Medical, part of TE Connectivity

    Medicoil

    K-Tube Technologies
    • Magazine
      • Current/Back Issues
      • Features
      • Editorial
      • Columns
      • Digital Editions
      • Subscribe Now
      • Advertise Now
    • News
    • Directory
      • All Companies
      • ALL CATEGORIES
      • Industry Associations
      • Company Capabilities
      • Add Your Company
    • Supply Chain
      • 3D/Additive Manufacturing
      • Contract Manufacturing
      • Electronics
      • Machining & Laser Processing
      • Materials
      • Molding
      • Packaging & Sterilization
      • R&D & Design
      • Software & IT
      • Testing
      • Tubing & Extrusion
    • Device Sectors
      • Cardiovascular
      • Diagnostics
      • Digital Health
      • Neurological
      • Patient Monitoring
      • Surgical
      • Orthopedics
    • Top 30 Company Report
    • Expert Insights
    • Slideshows
    • Videos
    • Podcasts
    • Resources
    • eBook
    • Infographics
    • Whitepapers
    • Research
      • White Papers
      • Case Studies
      • Product Spec Sheets
      • Market Data
    • MPO Summit
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Microsite
      • Companies
      • Product Releases
      • Product Spec Sheets
      • Services
      • White Papers / Tech Papers
      • Press Releases
      • Videos
      • Literature / Brochures
      • Case Studies
    • About Us
      • About Us
      • Contact Us
      • Advertise with Us
      • eNewsletter Archive
      • Privacy Policy
      • Terms of Use
    Columns

    Trends, Opportunities, and Drivers in Early-Stage Life Sciences Investing

    Despite trade wars and economic shifts in China and the EU, early-stage investing in life sciences remained strong in Q1 2019.

    Trends, Opportunities, and Drivers in Early-Stage Life Sciences Investing
    Related CONTENT
    • Medtech Matters: Surgeons Scrubbing In Virtually
    • Medtech Matters: Talking Robotic Surgery with Zimmer Biomet
    • Greenlight Guru and Nelson Labs Partner
    • Medtech Veteran Joins VivaLNK Board
    • New Global Headquarters for Freudenberg Medical
    Byron S. Kalogerou, Partner, McDermott Will & Emery09.06.19
    It’s a great time to be an early-stage life sciences company. Significant funding continues to roll into this sector, driven by legacy venture capital (VC) funds bringing in new dollars, new players that are out-raising their targets, and active corporate venture capital players. Despite trade wars and economic shifts in China and the EU, early-stage investing in life sciences, particularly in the biotechnology and medical devices sectors, remained strong in Q1 2019, improving quarter over quarter with more than $2.8 billion invested into the space. The confluence of funding and an innovation-friendly regulatory environment provide early-stage life sciences companies with ample opportunity to bring their solutions to market. This article explores the factors driving opportunity in this investment space, as well as how investors and companies can position themselves as attractive partners.

    Getting Innovation to Market and Subsectors to Watch
    Recent actions by the U.S. Congress and leadership at the U.S. Food and Drug Administration (FDA) have demonstrated regulatory support for innovative life sciences solutions. Numerous programs, such as the FDA’s Breakthrough Designation Program for medical devices and the Digital Health Precertification Program, among others, have allowed companies to work more closely with regulators, communicate with them prior to approval submissions, and bring products to market more rapidly, while still maintaining patient safety. These programs, which require fewer data submissions at the outset in exchange for increased post-market study and surveillance obligations, can allow companies with smaller budgets to get their product to market earlier.

    Coinciding with the shift in focus from treatment to cure, from status quo to innovation, the first generation of gene cell therapies have arrived, along with a new wave of digital health applications that employ artificial intelligence (AI) and machine learning (ML). New tools, diagnostics, and devices are reshaping the way patients receive treatment across the spectrum of care. These exciting breakthroughs are accelerating discovery and creating a better understanding of the mechanism of action—which, in turn, gives better insight into clinical outcomes, giving investors a more predictable return. Particularly ripe subsectors for investment as indicated by Q1 2019 performance and regulatory attention include:
    • AI and ML: From diagnosing tumors to matching patients to clinical trials, the staggering amount of data collected in the life sciences space presents numerous use cases for AI and ML solutions. While implementation challenges remain, a recent FDA white paper on its efforts to develop a framework for regulating AI products, along with two AI-based devices approved by the agency in 2018, are promising for investors and developers alike. Investors and analysts have taken note, with AI in the life sciences space valued at $902.1 million (forecasted 2019-2024).
    • Medical Devices: Funding for medical devices saw a 7 percent quarter over quarter increase to $701 million in Q1 2019. The FDA’s Breakthrough Device Program, which has granted 112 Breakthrough Designation Requests as of January 2019, is one example of the supportive regulatory environment and a contributing factor to the funding increases seen in this life sciences subsector.
    Transformation-Driven Partnerships: Evaluating and Attracting Targets
    Within this dynamic landscape, early-stage life sciences companies and investors are forming mutually profitable partnerships to bring transformative products to market faster and more efficiently. Life sciences companies can take strategic steps to enhance their value as a potential investment target. When evaluating targets, investors often look for the following elements:
    • Innovation and unmet need. Novel products, therapies, or approaches that address an unmet need in the market are good candidates for investment.
    • The right team. It is often easier to find good technology than good managers, according to some investors. A life sciences company with a well-run team and strong leadership in place makes for a more attractive investment partner. Effective leaders who can clearly articulate the path to commercialization and the cost to do so will attract investment dollars.
    • Cross-border application. More than ever, investors are looking for products that can enter multiple markets, including Europe and Asia Pacific, because an expanded geographic approach can increase returns. Devices and other products that have application to China’s burgeoning market are a particularly hot focus for investors.
    • Opportunities to add value. Many investors seek out targets that present compelling and quantifiable propositions to drive significant costs out of the healthcare system while improving health outcomes. Investors are not seeking opportunities for marginal savings, but rather transformative “move the needle” innovation.
    To set the stage for an effective investment partnership, life sciences companies should reach out early and often to potential investors, well before they are actually looking to raise capital. Attending industry and well-orchestrated partnering events like Life Science Nation’s RESI series can be a good opportunity to connect and develop relationships with a host of potential investors. Investors don’t just invest in a product—they invest in a team—so face-to-face interaction can lay valuable groundwork for a potential partnership. Curating those contacts through counsel, an accountant, and/or banker can reap dividends over time.

    In addition to evaluating whether a partnership is a good fit from a leadership and culture perspective, investors will often consider the following questions when evaluating a potential target—being prepared to speak directly and clearly to these points, as well as to specific goals for the partnership, will allow for a much more fruitful conversation with a potential investor.
    • What is the regulatory risk? What will it take to get the company through the next regulatory milestones in all relevant jurisdictions? Is it reasonable to expect the device or product to be approved globally at the same time, or will there be regulatory lag? What level of investment will it take to get the product into a clinic and generate the necessary clinical data? Investors today are increasingly conditioning funding on these regulatory milestones.
    • What is the reimbursement pathway? With regulatory approval achieved, revenue can only be achieved by executing a reimbursement strategy that addresses coverage, coding, and payment. After satisfying investors on the ability to secure coverage determination and coding, investors will focus on the pricing of a product to assess the sales potential.
    • Does the company have a clear inflection point it is trying to reach? If a life sciences company can’t articulate a specific, discrete strategy for how it will use the funding to develop or commercialize the product, investors may pass on the opportunity.
    • What is the competitive landscape? How big is the market opportunity in various jurisdictions? This evaluation should take into account not just the general consumer or patient pool, but also specific practicalities, such as the number of patients willing to pay a given price for the product, or the treatment paradigms that come into play. Having a good grasp of these specifics can improve conversations with potential investors, because it reduces the amount of uncertainty they will have to devote time and resources to address.
    • What is the exit opportunity? We often counsel our early-stage clients to “begin with the end in mind.” Life sciences investors will want to hear a clearly articulated vision of the exit. Will the company be seeking to access the capital markets in an initial public offering, looking for an exit through an acquisition, or seek to out-license the technology? In the case of an M&A exit or an out-license, companies should identify each of the potential suitors with whom they envision they will one day conduct a deal.

    Changing economic and political environments aside, the life sciences market presents exciting opportunities for early-stage life sciences companies and the investors who believe and invest in them. Early-stage firms with defined strategic goals, an innovative product addressing unmet need and a compelling value proposition, effective leadership, and above all, an exit strategy that enables investors to achieve the returns they are seeking, can position themselves to attract the right investors to bring their solutions to market. 


    Byron S. Kalogerou is the founder of the McDermott Will & Emery’s Life Science Industry Group and the senior attorney in the Boston Corporate Practice. He focuses his practice on domestic and cross-border mergers and acquisitions, finance, and joint ventures and alliances. He has substantial on-the-ground experience structuring mergers, acquisitions, divestitures, and joint ventures on six continents. Byron has extensive industry background in the life sciences, industrial, and manufacturing sectors. He also acts as outside general counsel to a number of companies.
    Related Searches
    • company
    • medical
    • ul
    • regulatory
    Suggested For You
    Medtech Matters: Medtronic Medtech Matters: Medtronic's Robotic Surgery Status
    Medtech Matters: Surgeons Scrubbing In Virtually Medtech Matters: Surgeons Scrubbing In Virtually
    Medtech Matters: Talking Robotic Surgery with Zimmer Biomet Medtech Matters: Talking Robotic Surgery with Zimmer Biomet
    Greenlight Guru and Nelson Labs Partner Greenlight Guru and Nelson Labs Partner
    Medtech Veteran Joins VivaLNK Board Medtech Veteran Joins VivaLNK Board
    New Global Headquarters for Freudenberg Medical New Global Headquarters for Freudenberg Medical
    Impact of COVID-19 on the Medtech Supply Chain Impact of COVID-19 on the Medtech Supply Chain
    Mike on Medtech: Communicating with the FDA Mike on Medtech: Communicating with the FDA
    Finding the Upside to a Challenging Year Finding the Upside to a Challenging Year
    BellaSeno Establishes High-Throughput Additive Manufacturing Facility for Resorbable Implants BellaSeno Establishes High-Throughput Additive Manufacturing Facility for Resorbable Implants
    Medtech Matters: Talking Medtech with Joe Mullings Medtech Matters: Talking Medtech with Joe Mullings
    Expert Roundup: Achieving Success in the 2021 Medical Device Landscape Expert Roundup: Achieving Success in the 2021 Medical Device Landscape
    Olympus Corporation to Acquire Veran Medical Technologies Olympus Corporation to Acquire Veran Medical Technologies
    Setting the Standard: Protective Nanocoatings for Today Setting the Standard: Protective Nanocoatings for Today's Medtech
    Medtech Matters: A Robotic Surgery Subscription Medtech Matters: A Robotic Surgery Subscription

    Related Columns

    • Fixing Face Mask Form and Function

      Fixing Face Mask Form and Function

      Masks for the general public are varied in both style and effectiveness.
      Sam Brusco, Associate Editor 11.04.20

    • Cardiovascular
      The Heart of the Matter: Trends in Cardiology

      The Heart of the Matter: Trends in Cardiology

      Of the three major segments of coronary stents, bioabsorbable stents are expected to have the highest growth between now and 2022.
      Maria Shepherd, President and Founder, Medi-Vantage 11.04.20

    • Virtually the Same? The Challenges of Online Conferences

      Virtually the Same? The Challenges of Online Conferences

      Like everyone else on the planet, I’m turning increasingly to virtual solutions to our physical challenges in the midst of a pandemic.
      Dawn A. Lissy, Founder & President, Empirical 11.04.20


    • Digital Health
      Digital Health Delivers During a Year for the Ages

      Digital Health Delivers During a Year for the Ages

      Internet of Medical Things technologies have emerged as the key enabler of a much more holistic and complete disease-state management toolbox.
      Brad Womble, Senior Director of Strategy, Marketing, and Mergers & Acquisitions, Jabil Healthcare 11.04.20

    • Advanced Technology for Staking and Swaging Medical Plastics

      Advanced Technology for Staking and Swaging Medical Plastics

      It reliably assembles heat- and vibration-sensitive components, and works with a wide range of plastic materials.
      Priyank Kishor, Global Product Manager—PulseStaking, Branson at Emerson 11.04.20

    • Quality Assurance When Supply Chain Disruptions Arise

      Quality Assurance When Supply Chain Disruptions Arise

      From supply chain disruptions to impromptu manufacturing modifications, the medical device industry has faced a whirlwind of complications in 2020.
      Sandi Schaible and Peter Steen, WuXi AppTec Medical Device Testing 11.04.20


    • The Top 30 and M&A in 2021: What’s Next?

      The Top 30 and M&A in 2021: What’s Next?

      With three of the top five companies appointing new CEOs in the last year and the global pandemic eroding earnings, M&A strategies could look a lot different.
      Florence Joffroy-Black and Dave Sheppard, MedWorld Advisors 11.04.20

    • COVID 19: Supply Chain Professionals’ Ultimate Reality Challenge

      COVID 19: Supply Chain Professionals’ Ultimate Reality Challenge

      Having been a part of the medtech supply chain for 40 years, I can say there has never been a more difficult time for supply chain professionals.
      Chris Oleksy, Founder and CEO, Oleksy Enterprises and Next Life Medical; CEO, Emergent Respiratory 11.04.20

    • Congress Examines Additional COVID-19 Relief and Recent Regulatory Changes

      Congress Examines Additional COVID-19 Relief and Recent Regulatory Changes

      The legislative year is nearly coming to a close as Washington survives yet another tumultuous election cycle.
      Jeffrey J. Kimbell, Eric P. Juhl, JD and David C. Rudloff, Jeffrey J. Kimbell & Associates Inc. 11.04.20


    • 3D/Additive Manufacturing
      Additive Manufacturing: Debinding Fluids Must-Haves

      Additive Manufacturing: Debinding Fluids Must-Haves

      As the pressure to produce more complex biomedical parts increases, medical device manufacturing using 3D printing is gaining widespread acceptance.
      Venesia Hurtubise, Technical Chemist, MicroCare Medical 11.04.20

    • Diagnostics
       How COVID-19 is Reshaping the Diagnostics Testing Sector

      How COVID-19 is Reshaping the Diagnostics Testing Sector

      The short-term impact on the diagnostics sector is readily apparent as the pandemic has fueled overwhelming demand for effective SARS-CoV-2 testing solutions.
      Eric Williams, Managing Director, Capstone Headwaters 11.04.20

    • Will Industry’s COVID-19 Recovery End Prematurely?

      Will Industry’s COVID-19 Recovery End Prematurely?

      Finally, a light at the end of the tunnel, but will it remain lit?
      Michael Barbella, Managing Editor 10.01.20


    • Surgical
      Hype or Hope? The Future of Surgical Robotics

      Hype or Hope? The Future of Surgical Robotics

      Recent publications suggest the U.S. performs more robotic surgery than every other country in the world.
      Maria Shepherd, President and Founder, Medi-Vantage 10.01.20

    • COVID Community: How the Pandemic Is Bringing Out the Best in Us

      COVID Community: How the Pandemic Is Bringing Out the Best in Us

      Given the brain power and generosity of our industry, I knew I could follow the wisdom of Fred Rogers’ mother and “look for the helpers.”
      Dawn A. Lissy, Founder & President, Empirical 10.01.20

    • Electronics
      Why Applying Cleanliness Standards to Outsourced Medical Electronics Is Important

      Why Applying Cleanliness Standards to Outsourced Medical Electronics Is Important

      When looking to outsource the manufacture of electronic medical devices, cleanliness standards and processes should be a top consideration.
      Jay Tourigny, Senior Vice President, MicroCare Medical 10.01.20


    Trending
    • Telemedicine, Regulatory Changes To Characterize Medtech Industry In 2021
    • Masimo Earns CE Mark For New Fingertip Pulse Oximeter
    • Philips Buys Capsule Technologies In $635M Deal
    • Understanding Food-Grade Vs. Biocompatibility For Medical Device Materials
    • Medtech Matters: Surgeons Scrubbing In Virtually
    Breaking News
    • Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    • Endoscopic Hemostasis Devices Market Valued at $730 Million
    • Henry Schein Buys Majority Interest in Prism Medical Products
    • Boston Scientific's Vercise Genus DBS Earns FDA Approval
    • Biotech Team Develops ELISA Protocol for COVID-19 Antibody Detection
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Pharmaceutical Focus: A Look at Combination Products
    • The Printed World: Additive Manufacturing in Medtech
    • The Lost Year: 2020 Year in Review
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Nouryon Appoints Curtis Espeland to Board of Directors
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Henry Schein Buys Majority Interest in Prism Medical Products
    Contract Pharma

    Latest Breaking News From Contract Pharma

    CONTINUUS Awarded $69.3M DoD Grant
    AbbVie Licenses ProBioGen’s GlymaxX Technology
    WDSrx Expands Warehouse Network
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Coty Appoints Chief Procurement Officer
    Amyris To Enter Cannabinoid Beauty
    RB Buys Queen V
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Siemens Healthineers’ DR Systems Cleared by FDA
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures
    IHSMarkit Reports Top Clean-Tech Trends for 2021

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login